Daré Bioscience (DARE) to Release Earnings on Thursday

Daré Bioscience (NASDAQ:DARE) will be posting its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Daré Bioscience to post earnings of ($0.60) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $2.09. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.60 million. On average, analysts expect Daré Bioscience to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Daré Bioscience Price Performance

NASDAQ:DARE opened at $4.41 on Wednesday. Daré Bioscience has a one year low of $3.05 and a one year high of $7.56. The company has a market cap of $37.71 million, a PE ratio of -3.92 and a beta of 1.34. The firm’s 50 day simple moving average is $3.54 and its 200 day simple moving average is $3.92.

Analysts Set New Price Targets

DARE has been the topic of several analyst reports. Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a research report on Thursday, October 24th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.